{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:30:55Z","timestamp":1793633455902,"version":"4.5.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032975","name":"Bill and Melinda Gates Foundation \u2014 India Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-029358"],"award-info":[{"award-number":["INV-029358"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103102","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:48:19Z","timestamp":1789688899000},"page":"103102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RNA-encoded PGT121-LS anti-HIV antibody: Comprehensive preclinical characterization and translational pharmacokinetics"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4309-0685","authenticated-orcid":false,"given":"Felix","family":"Tolksdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-0299","authenticated-orcid":false,"given":"Johannes","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4183-8613","authenticated-orcid":false,"given":"Robin","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Caesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-3010","authenticated-orcid":false,"given":"Anuhar","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-7109","authenticated-orcid":false,"given":"Anja","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Malz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Kratochvil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Gerhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-9023","authenticated-orcid":false,"given":"Jan P.","family":"Bogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-1931","authenticated-orcid":false,"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-1311","authenticated-orcid":false,"given":"Nicole L.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-0628","authenticated-orcid":false,"given":"Joshua A.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Ellinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-8729","authenticated-orcid":false,"given":"Christiane R.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0363-1564","authenticated-orcid":false,"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-0655","authenticated-orcid":false,"given":"Valentin","family":"Le Douce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103102_bib1","article-title":"AIDS, crisis and the power to transform: UNAIDS Global AIDS Update 2025","year":"2025","journal-title":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)"},{"key":"10.1016\/j.omtn.2026.103102_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118190","article-title":"From antiretrovirals to curative therapies: Current developments in HIV treatment and prevention","volume":"300","author":"Mundlia","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omtn.2026.103102_bib3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm.1949","article-title":"Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?","volume":"15","author":"Stamatatos","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","article-title":"Future of bNAbs in HIV Treatment","volume":"22","author":"Tebas","year":"2025","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.omtn.2026.103102_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review","volume":"22","author":"Mahomed","year":"2025","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.omtn.2026.103102_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2255041","article-title":"Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody","volume":"12","author":"B\u00e4hr-Mahmud","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omtn.2026.103102_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2026.103102_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65456-x","article-title":"Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV\/HIV protection","volume":"16","author":"Joo","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103102_bib12","article-title":"Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates","volume":"16","author":"Rouzeau","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103102_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.103102_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/antib10040037","article-title":"Engineered mRNA and the Rise of Next-Generation Antibodies","volume":"10","author":"Sanz","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.omtn.2026.103102_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103102_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2026.103102_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib19","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib20","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","volume":"10","author":"Sobieszczyk","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.omtn.2026.103102_bib21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2026.103102_bib22","unstructured":"Du, X.A., Steven M. (2017) LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS. patent application PCT\/US20 16\/039999."},{"key":"10.1016\/j.omtn.2026.103102_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4049\/jimmunol.1800896","article-title":"Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies","volume":"202","author":"Bas","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103102_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103102_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.omtn.2026.103102_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans","volume":"15","author":"Ward","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.omtn.2026.103102_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2026.103102_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env","volume":"22","author":"Kwon","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omtn.2026.103102_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1742-4690-11-41","article-title":"Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits","volume":"11","author":"Yasmeen","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.omtn.2026.103102_bib30","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/19420862.2016.1229721","article-title":"Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics","volume":"8","author":"Myzithras","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2026.103102_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV","volume":"16","author":"Mayer","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2026.103102_bib32","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41467-019-13108-2","article-title":"An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103102_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41092-7","article-title":"Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies","volume":"13","author":"Thran","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103102_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112764","article-title":"Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies","volume":"479","author":"Bharadwaj","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.omtn.2026.103102_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","article-title":"Treatment of a metabolic liver disease in mice with a transient prime editing approach","volume":"9","author":"Rothgangl","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2026.103102_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues","volume":"30","author":"Chander","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.103102_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101470","article-title":"Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice","volume":"33","author":"Stone","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.103102_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103102_bib39","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103102_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103102_bib41","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103102_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00152-22","article-title":"Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives","volume":"37","author":"Mahomed","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omtn.2026.103102_bib43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI132779","article-title":"In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity","volume":"130","author":"Wise","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103102_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.intimp.2011.01.014","article-title":"Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model","volume":"11","author":"Wang","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2026.103102_bib45","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib46","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1089\/hum.2014.146","article-title":"Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice","volume":"26","author":"Liu","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.103102_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.09.004","article-title":"Construction and application of adenoviral vectors","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103102_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.103102_bib49","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103102_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12026-025-09737-z","article-title":"mRNA-Encoded antibodies as a next-generation therapeutic paradigm: a rapid and adaptive platform for the prevention and treatment of emerging and re-emerging infectious diseases - A critical review","volume":"74","author":"Singh","year":"2026","journal-title":"Immunol. Res."},{"key":"10.1016\/j.omtn.2026.103102_bib51","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae100","article-title":"Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau","volume":"6","author":"Wongsodirdjo","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.omtn.2026.103102_bib53","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2025.43.16_suppl.2501","article-title":"First-in-human phase I\/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors","volume":"43","author":"Yap","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.103102_bib54","article-title":"Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1","volume":"11","author":"Narayanan","year":"2022","journal-title":"Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1"},{"key":"10.1016\/j.omtn.2026.103102_bib55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ymthe.2020.01.002","article-title":"Aerosol Delivery of Synthetic mRNA to Vaginal Mucosa Leads to Durable Expression of Broadly Neutralizing Antibodies against HIV","volume":"28","author":"Lindsay","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103102_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00268-21","article-title":"Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding","volume":"95","author":"Rosenberg","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.103102_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1326144","article-title":"A comparative analysis of intravenous infusion methods for low-resource environments","volume":"11","author":"Tomobi","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2023.06.034","article-title":"Drug delivery breakthrough technologies - A perspective on clinical and societal impact","volume":"360","author":"Bittner","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103102_bib59","first-page":"130s","article-title":"Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.omtn.2026.103102_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13788","article-title":"Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20","volume":"17","author":"Nolan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omtn.2026.103102_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224745","article-title":"Protein synthesis rates of muscle, tendon, ligament, cartilage, and bone tissue in vivo in humans","volume":"14","author":"Smeets","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103102_bib62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7150\/ijbs.3660","article-title":"Measurement of hepatic protein fractional synthetic rate with stable isotope labeling technique in thapsigargin stressed HepG2 cells","volume":"8","author":"Song","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omtn.2026.103102_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70356","article-title":"Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic-Toxicokinetic (PK-TK) Model: A Case Study With Anti-Claudin 18.2","volume":"18","author":"Desai","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omtn.2026.103102_bib64","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(24)00247-9","volume":"12","author":"Edupuganti","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.omtn.2026.103102_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2018.06.001","article-title":"Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression","volume":"195","author":"Tanko","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtn.2026.103102_bib66","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s43856-025-01261-3","article-title":"Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV","volume":"5","author":"Richter","year":"2025","journal-title":"Commun. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/v17060839","article-title":"HIV, Inflammation, and Immunometabolism: A Model of the Inflammatory Theory of Disease","volume":"17","author":"Teer","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2026.103102_bib68","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103102_bib71","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib72","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.ymthe.2024.05.036","article-title":"In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection","volume":"32","author":"Tkaczyk","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103102_bib73","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.103102_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117335","article-title":"mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures","volume":"45","author":"Cohen","year":"2026","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103102_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.omtn.2026.103102_bib76","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.103102_bib77","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103102_bib78","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103102_bib79","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mi.2012.107","article-title":"HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life","volume":"6","author":"Yates","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.omtn.2026.103102_bib80","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.omtn.2026.103102_bib81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40259-022-00566-2","article-title":"Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations","volume":"37","author":"Haraya","year":"2023","journal-title":"BioDrugs"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:11:29Z","timestamp":1793632289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002738"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103102","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-encoded PGT121-LS anti-HIV antibody: Comprehensive preclinical characterization and translational pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103102"}}